CDKN2B and ovarian carcinoma: We found that a low expression level of CDKN2B and WNT11 was associated with longer survival in ovarian cancer patients, while high expression levels of SMAD3, ZFYVE16, BMP6, LEFTY1, and DVL2 were significantly associated with poor survival (Fig. 6D, E).